Many women experience severe vasomotor symptoms during their menopausal transition. However, doctors cannot prescribe standard estrogen-containing menopausal hormone therapy to everyone due to safety concerns. Therefore, clinicians must explore alternative options for their patients. Specifically, progestogen monotherapy offers a viable and highly effective clinical solution for individuals with strict contraindications to estrogen. This treatment pathway helps alleviate distressing symptoms while maintaining a reassuring safety profile.
Clinical Indications for Progestogen Monotherapy
Doctors frequently encounter menopausal patients who present with specific contraindications to estrogen. For example, patients with a personal history of venous thromboembolism, coronary artery disease, or compensated liver disease require careful management. Additionally, those with gynecologic conditions like endometriosis or certain low-grade uterine malignancies cannot safely use estrogen. Consequently, clinicians must seek non-estrogenic hormonal therapies to manage their symptoms. Fortunately, recent narrative reviews confirm that progestogen-only regimens successfully fill this therapeutic gap.
Therapeutic Efficacy and Preparation Choices
Clinical evidence demonstrates that various progestogen formulations effectively reduce annoying hot flashes and night sweats. Specifically, oral, intramuscular, and transdermal preparations provide significant relief for vasomotor symptoms. Furthermore, micronized progesterone offers distinct secondary benefits by improving overall sleep quality in postmenopausal women. In contrast, synthetic progestins like medroxyprogesterone acetate or norethindrone acetate offer robust protection for bone health. Therefore, clinicians can easily customize the choice of progestogen based on individual patient needs.
Safety Profile and Key Contraindications
Before starting treatment, clinicians must carefully evaluate potential contraindications to ensure patient safety. Primarily, unexplained abnormal vaginal bleeding and a personal history of breast cancer represent absolute contraindications to this therapy. Additionally, practitioners should exercise strong caution in patients diagnosed with meningioma. However, the exact breast cancer risk associated with pure progestogen use remains unclear due to limited clinical trial data. Thus, practitioners must engage in shared decision-making and closely monitor patients during long-term therapy.
Frequently Asked Questions
Q1: What are the main indications for prescribing progestogen monotherapy during menopause?
Generally, clinicians prescribe this therapy to women who suffer from severe vasomotor symptoms but have contraindications to estrogen. Specifically, these contraindications include a history of venous thromboembolism, coronary artery disease, endometriosis, and certain gynecologic cancers. Therefore, it serves as an excellent alternative treatment option.
Q2: Which progestogen preparation is best for sleep disturbances?
Indeed, micronized progesterone provides significant secondary benefits for sleep quality. Moreover, clinical data suggest it acts as a mild sedative. Consequently, many physicians prefer oral micronized formulations to target nighttime awakenings and insomnia in menopausal women.
References
- Thomas C et al. Indications and Efficacy of Progestogen-Monotherapy as Menopause Hormone Therapy: A Narrative Review. BJOG. 2026 Jun 25. doi: 10.1111/1471-0528.70292. PMID: 42347558.
- Basheer S, et al. Menopausal Hormone Therapy: Current Review and its Acceptability and Challenges in the Indian Context. J Epidemiol Found India. 2025;3(1):24-30.
- Indian Menopause Society. Clinical Practice Guidelines on Menopause: Executive Summary and Recommendations. J Mid-life Health. 2020;11(2):55-112.